Publications by authors named "A Al-Hajje"
Purpose: Children with epilepsy are at an increased risk of developing psychiatric comorbidities, which exacerbate the overall disease burden. However, these disorders are often underreported in developing countries. This study, conducted in a developing country, aims to evaluate the frequency of psychiatric disorders and associated factors in a large cohort of children with epilepsy.
View Article and Find Full Text PDFObjective: Previous studies assessing factors associated with drug-resistant epilepsy (DRE) were constrained by their amalgamation of all epilepsy syndromes in their analyses and the absence of uniform criteria for defining DRE. Our objective was to identify predictors of DRE among the four primary childhood epilepsy syndrome groups within a cohort of children with new onset seizures, using the International League Against Epilepsy (ILAE) definition of DRE and the recent classification of epilepsies.
Methods: This is a prospective study of 676 children with new onset seizures initiated on antiseizure medication.
Background: There is a lack information regarding risk factors associated with worse COVID-19 outcomes in patients with multiple sclerosis (MS) in the MENA region.
Methods: This is a multicenter, retrospective cohort study that included all MS patients with a suspected or confirmed COVID-19 infection using the MENACTRIMS registry. The association of demographics, disease characteristics, and use of disease-modifying therapies (DMTs) with outcomes and severity of COVID-19 were evaluated by multivariate logistic model.
Article Synopsis
- The study focuses on finding the best disease-modifying therapies (DMTs) to switch to after stopping natalizumab (NTZ) due to John Cunningham virus (JCV) antibody positivity.
- A multicenter study involved 321 relapsing-remitting multiple sclerosis patients, comparing the outcomes of those who switched to rituximab/ocrelizumab, fingolimod, and alemtuzumab.
- Results indicated that patients switching to rituximab/ocrelizumab or alemtuzumab experienced lower relapse rates and less disability progression, making them more effective options than fingolimod.
Background: Multiple sclerosis (MS) management varies markedly between different countries of the Middle East and North Africa (MENA) region based on the availability and accessibility of disease-modifying therapies (DMTs).
Objective: To evaluate the accessibility to DMTs in each MENA country, identify barriers to treatment and make recommendations for improved access to DMTs across the region.
Methods: This is a descriptive, survey-based study whereby we extracted data collected, between October 2019 and April 2020, for countries in the MENA region by the Multiple Sclerosis International Federation (MSIF) through their Atlas of MS survey.